E. Nakamura, N. Tanaka N, M. Kuwabara M, A. Yamashita, Y. Matsuo, T. Kanai, T. Onitsuka, Y. Asada, H. Hisa and R. Yamamoto, “Relative contributions of 5-hydroxytryptamine (5-HT) receptor subtypes in 5-HT-induced vasoconstriction of the distended human saphenous vein as a coronary artery bypass graft,” Biol Pharm Bull, Vol. 34, No. 1, 2011, pp. 82-86.
 C. A. Hamilton, G. O’Dowd, L. McIntosh, G. Berg, J. Butler, V. Pathi, R. Williams, J.L. Reid and A.F. Dominiczak, “Vasorelaxant properties of isolated human radial arteries: comparison with internal mammary arteries,” Atherosclerosis, Vol. 160, No. 2, 2002, pp. 345-353.
 S. Attaran, L. John and A. El-Gamel, “Clinical and potential use of pharmacological agents to reduce radial artery spasm in coronary artery surgery,” Ann Thorac Surg, Vol. 85, No. 4, 2008, pp. 1483-1489.
 J.T. Parissis, I. Andreadou, S.L. Markantonis, V. Bistola, A. Louka, A. Pyriochou, I. Paraskevaidis, G. Filippatos, E.K. Iliodromitis and D.T. Kremastinos, “Effects of levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure,” Atherosclerosis, Vol. 195, No. 2, 2007, 210-215.
 K.H. Konz, M. Haap, K.E. Hill, R.F. Burk and R.A. Walsh, “Diastolic dysfunction of perfused rat hearts induced by hydrogen peroxide. Protective effect of selenium,” J Mol Cell Cardiol, Vol. 21, No. 8, 1989, pp. 789- 795.
 M.A. Rodriguez-Martinez, E.C. Garcia-Cohen, A.B. Baena, R. Gonzalez, M. Salaices and J. Marin, “Contractile responses elicited by hydrogen peroxide in aorta from normotensive and hypertensive rats. Endothelial modulation and mechanism involved,” Br J Pharmacol, Vol. 125, No. 6, 1998, pp.1329-1335.
 A.S. Sahin, E.A. Atalik, T.K. Sahin and N Do?an, “Cooling and response to hydrogen peroxide in human saphenous vein: role of the endothelium.,” Fundam Clin Pharmacol, Vol. 19, No. 3, 2005, pp.341-346
 K. Watanabe, Y. Okatani and Y. Sagara, “Potentiating effect of hydrogen peroxide on the serotonin-induced vasocontraction in human umbilical artery,” Acta Obstet Gynecol Scand, Vol. 75, No. 9, 1996, pp. 783-789.
 J.T. Parissis, I. Andreadou, V. Bistola, I. Paraskevaidis, G. Filippatos and D.T. Kremastinos, “Novel biologic mechanisms of levosimendan and its effect on the failing heart,” Expert Opin Investig Drugs, Vol. 17, No. 8, 2008, pp. 1143-1150.
 R.S. Barlow, A.M. El-Mowafy, RE and White, “H2O2 opens BKca channels via the PLA2-arachidonic acid signaling cascade in coronary artery smooth muscle,” Am J Physiol Heart Circ Physiol, Vol 279, No. 2, 2000, pp. H475-483.
 A. Hara, T. Suzuki, H. Hashizume, N. Shishido, M. Nakamura, F. Ushikubi and Y. Abiko, “Effects of CP-060S, a novel Ca2+ channel blocker, on oxidative stress in cultured cardiac myocytes,” Eur J Pharmacol, Vol. 385, No. 1, 1999, pp. 81-88.
 S. Shimizu, Y. Saitoh, T. Yamamoto and K. Momose, “Stimulation by hydrogen peroxide of L-arginine metabolism to L-citrulline coupled with nitric oxide synthesis in cultured endothelial cells,” Res Commun Chem Pathol Pharmacol, Vol. 84, No. 3, 1994, pp. 315-329.
 Z.W. Yang, T. Zheng, J. Wang, A. Zhang, B.T. Altura and B.M. Altura, “Hydrogen peroxide induces contraction and raises [Ca2+] i in canine cerebral arterial smooth muscle: participation of cellular signaling pathways,” Naunyn Schmiedebergs Arc Pharmacol, Vol. 360, No. 6, 1999, pp. 646-653.
 H. Mirkhani, M. Shafa and H. Khazraei, “Comparison of the effects of levosimendan and papaverine on human internal mammary artery and saphenous vein,” Cardiovasc Drugs Ther, Vol. 23, No. 5, 2009, pp. 355-359.
 E.P. Sandell, M. Hayha, S. Antila, P. Heikkinen, P Ottoila, L.A. Lehtonen and P.J. Pentikainen, “Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure,” J Cardiovasc Pharmacol, Vol. 26, No. Supl 1, 1995, pp. 557-562.
 G. Lilleberg, S. Sundberg and M.S. Nieminen, “Dose- range study of a new calcium sensitizier, levosimendan, in patients with left ventricular dysfunction,” J Cardiovasc Pharmacol, Vol. 26, No. Suppl. 1, 1995, pp. S563- 569.
 C. Avgeropoulou, I. Andreadou, S. Markantonis-Ky- roudis, M. Demopoulou, P Missovoulos, A. Androulakis and I. Kallikazaros, “The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine,” Eur J Heart Fail, Vol. 7, No. 5, 2005, pp. 882-887.
 A.S. Sahin, N. Gormus and A. Duman, “Preconditioning with levosimendan prevents contractile dysfunction due to H2O2-induced oxidative stress in human myocardium” J Cardiovasc Pharmacol, Vol. 50, No. 4, 2007, pp. 419- 423.
 J. Pataricza, J. Szolnoky, I. Krassoi, Z. Hegedus, A. Kun, A. Varro and J.G. Papp, “Vazorelaxing effect of levosi- mendan against 5-hydroxytryptamine-induced contractions in isolated human conduit bypass grafts,” J Pharm Pharmacol, Vol 58, No. 8, 2006, pp. 1107-1112.